TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05679869

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masking Sound
Description: Prerecorded environmental noise and masking sounds played from headphones

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No masking sound
Description: Prerecorded environmental noise but no masking sounds played from headphones
Study: NCT05086107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BV100
Description: Rifabutin for infusion
Study: NCT05940480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TCM Daoyin
Description: The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education
Description: Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.
Study: NCT05479019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimuli
Description: Stimuli will be shown to participants and they will be asked to perform a visual task.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual stimuli
Description: Stimuli will be shown to participants and they will be asked to perform a visual task.
Study: NCT04591808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin/Perindopril
Description: 1 over-encapsulated S05167 capsule, fixed dose combination of Atorvastatin/Perindopril Arginine 40/10 mg, will be administered once daily each day before breakfast during 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: 1 over-encapsulated atorvastatin 40 mg tablet will be administered once daily each day before breakfast during 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 1 over-encapsulated perindopril 10 mg tablet will be administered once daily each day before breakfast during 8 weeks.
Study: NCT05847946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape application and Core stabilization home program
Description: Participants in the kinesiotape group will receive 2 sessions of kinesiotape per week, in addition to the core stabilization home program, 5 days a week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stabilization home program
Description: Core stabilization exercises will be given to the participants as a home exercise program.
Study: NCT05379998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural mobilization
Description: Sciatic nerve mobilization (sliding technique) will be performed by a physical therapist. The sciatic nerve mobilization technique improves the nerve mobility of the hemiparetic lower limb in a nervous system patient and is helpful in increasing the ROM of the lower limbs without resistance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF hold relax technique
Description: Proprioceptive neuromuscular facilitation hold relaxation technique of hamstring muscle will be performed by the physical therapist three days a week for 6 weeks. In the hold relax technique after reaching the point of resistance, an isometric contraction is performed against the resistance to get a pain free response.
Study: NCT05474157

Intervention type: OTHER
Intervention: Standard care treatment for COVID-19 in Intensive Care Unit
Description: Standard care for ARDS patients consisted of respiratory support, intravenous fluid therapy, medical treatment including anticoagulation and sedation, nutrition, change of position every 4 hours and if needed, hemodynamic support.
Study: NCT05506033

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rapid GCs taper
Description: After a complete response was achieved, the GCs dose was halved from the original dose.
Study: NCT06125717

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H1 influenza antigen
Description: Either 7.5 μg or 15 μg of the H1 influenza antigen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H1 influenza antigen
Description: Either 7.5 μg or 15 μg of the H1 influenza antigen

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: H1 influenza antigen
Description: Either 7.5 μg or 15 μg of the H1 influenza antigen
Study: NCT05953623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: This is a 3 + 3 dose-escalation study with 5 doses (0.25g/kg, 0.35g/kg, 0.40g/kg, 0.45g/kg, 0.5g/kg). Intra-arterial albumin infusion will be applied after successful recanalization of the culprit artery in the anterior circulation.
Study: NCT05824819

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Next Generation Sequencing (NGS)
Description: Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Next Generation Sequencing (NGS)
Description: Biological materials (stool, peritoneal/ovarian cyst fluid, endometrial aspirate) will be secured and then subjected to molecular analysis using the Next Generation Sequencing (NGS) method. The stages will include: i) isolation of bacterial DNA from biological materials, ii) preparation of libraries for sequencing, including the performance of the PCR and nested-PCR methods on bacterial DNA isolates from the tested samples of biological materials, iii) purification of amplification products, indexing, validation of the concentration of amplicons, pooling and denaturation of libraries, iv) standardization and optimization of the procedure for the isolation of bacterial metagenomic DNA from biological materials from intestines, peritoneal cavity, uterine cavity and endometrial tissues, v) standardization of the nested-PCR method on bacterial DNA isolates from the tested biological materials, vi) submission of samples for sequencing.
Study: NCT04840823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxacin
Description: Oral 200mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxacin
Description: Oral 200mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxacin
Description: Oral 200mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablet
Study: NCT06400043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive dual-task
Description: Participants will be asked to walk at comfortable walking speed while playing an additional cognitive task, namely the Stroop Color and Word Test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor dual-task
Description: Participants will be asked to walk at comfortable walking speed while playing an additional motor task, namely a game that requires arm swing to hit the targets.
Study: NCT05105204

Intervention type: DEVICE
Intervention: ArteVu
Description: The study participants will concurrently undergo noninvasive blood pressure monitoring with the ArteVu finger clip applied to the same extremity that is being used to measure the radial artery pressure.
Study: NCT05298956

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Low-level laser therapy (LLLT)
Description: Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-level laser therapy (LLLT)
Description: Sham Comparator: Participants will receive 8 counts of 60 seconds of the same laser to the right forehead, however the laser power will be turned off and will be 0 Watts.~Transcranial infrared laser stimulation: Participants will receive 8 counts of 60 seconds of transcranial infrared laser stimulation to the right forehead. The wavelength will be 1064 nm and the laser power will be 3.4 Watts.
Study: NCT05451901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate necrosectomy
Description: Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the immediate necrosectomy group, endoscopic necrosectomy (EN) will be performed in the same session of EUS-guided drainage using a gastroscope. The endoscope is inserted into the WON cavity through the LAMS, and necrotic tissue is removed using biopsy forceps, snare, or basket catheter. The EN procedures will be repeated until clinical improvement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Step-up approach
Description: Endoscopic ultrasonography (EUS)-guided drainage will be conducted within 72 hours from randomization. A convex-type echoendoscope is advanced to the stomach or duodenum, and the walled-off necrosis (WON) is visualized and punctured under EUS guidance. A lumen-apposing metal stent (LAMS), such as Hot AXIOS system (Boston Scientific Japan, Tokyo, Japan), is recommended for the initial EUS-guided drainage.~For the step-up approach group, an additional interventional procedure will be withheld for 72-96 hours after initial EUS-guided drainage. In cases without clinical improvement after 72-96 hours, additional drainage will be permitted, which includes increasing the number of stents, additional EUS-guided drainage, and performing percutaneous drainage (step-up treatment). Insufficient improvement even after two times of step-up treatment allows subsequent endoscopic necrosectomy (EN).
Study: NCT05503823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS or tRNS and TMS
Description: A light electrical current will be applied to the scalp of the participants via 2 electrodes. The resting and active motor threshold will be measured before, right after, after 30 minutes, and after 1 hour of receiving the tACS or tRNS.
Study: NCT05103046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCT-03-008
Description: Orally available kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCT-03-008
Description: Orally available kinase inhibitor
Study: NCT06218966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intracochlear catheter
Description: intracochlear administration of steroids through the intracochlear catheter INCAT
Study: NCT05825378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg+0.375% ropivacaine
Description: Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml of a mixture of 0.375% ropivacaine and 8 mg dexamethasone was injected at each point

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.375% ropivacaine
Description: Ultrasound-guided intercostal nerve block was performed on the surgical side, and 3 to 5ml 0.375% ropivacaine was injected at each point
Study: NCT06491485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group M (lidocaine with Magnesium sulfate)
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with magnesium sulfate 50 mg/kg (maximum 2g) will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (lidocaine with Sodium bicarbonate)
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine with 50 ml 4.2% sodium bicarbonate will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C (lidocaine with saline)
Description: a total volume 200 ml normal saline 0.9% at a temperature of 37°c including 3mg/kg of 1% lidocaine will be sprayed by the surgeon through the laparoscopic port to wash the incisions and anastomosis.
Study: NCT05701995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib
Description: Specified dose on specified days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days.
Study: NCT06383481

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile based education
Description: Control Group Patients in the control group will be provided with standard patient care and information. No application will be made.~Experimental group The mobile application will be downloaded to the phones of patients who can use the mobile application. The mobile application will be available to the patient. Patients will be informed about daily monitoring of the mobile application, following the training steps, and that they can reach the researcher with consultancy services whenever they need. The mobile application will be made available to patients within a 12-week period and patient follow-up will be provided.
Study: NCT05952882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide + Metformin
Description: Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week. Concomitantly, Liraglutide was initiated at a subcutaneous dose of 0.6 mg once daily for 1 week, then titrated in increments of 0.6 mg once daily every 1 to 3 weeks to a maintenance dose of 3.0 mg once daily for up to 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin XR (extended-release) was initiated at 750 mg once daily and increased to 1500 mg once daily after 2 week
Study: NCT04922385

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: This study is an open waitlist control study. Eligible participants will be assigned to a treating clinician and will complete 4 weeks of treatment, followed by a post-treatment assessment (2 weeks later). If a treating clinician is not immediately available, participants will be placed on their waitlist for 4 weeks. They will then be assessed after 4 weeks and undergo the 4 week treatment, followed by the post-treatment assessment (2 weeks later).
Study: NCT06513091

Intervention type: DEVICE
Intervention: OCS Lung
Description: The TransMedics Organ Care System (OCS) Lung is an FDA approved portable extracorporeal lung perfusion and monitoring system.
Study: NCT06655844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sana Pain Reliever
Description: The Sana Pain Reliever (Sana PR) by Sana Health Inc is a device comprised of one (1) main component (Mask with Earbuds) and two (2) ancillary components (Charger and Headband). The device is worn over the eyes (with earbuds in ears).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SPR
Description: Participants will receive the SPR device and a tablet with instructions of how to use the device and how to answer the questionnaires on the tablet mobile application. Each session with the device will last 15 minutes and run under the device's sham settings. The session consists of periods of light and sounds (beeps). Participants will be instructed to use the device each day at the end of the day prior to going to sleep and whenever they experience heightened pain during the day.
Study: NCT06654375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy
Description: Endovascular thrombectomy (EVT) in this clinical trial involves the mechanical removal of a thrombus from a blocked large cerebral artery using specialized devices like stent retrievers or aspiration catheters. Key distinguishing features of this EVT protocol include:~* Extended Time Window: Unlike standard EVT, which is typically performed within 24 hours after symptom onset, this intervention targets patients presenting beyond 24 hours.~* Collateral Circulation Assessment: Multi-phase CT angiography (CTA) is employed to evaluate collateral flow, prioritizing patients with favorable collateral grades. This selection process helps ensure the identification of patients most likely to benefit from EVT despite the late presentation.
Study: NCT06654661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Printed Mechanical Balancer
Description: The 3D printed mechanical balancer is a surgeon-controlled handheld intraoperative tool used that provides a quantifiable measurement of force differences on the medial and lateral sides to guide achievement of a balanced knee. It will be used at one timepoint during scheduled TKA surgery while the patient is under anesthesia. Readings will be taken at 0, 45, and 90 degrees of flexion.
Study: NCT06589089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell
Description: Intervention were given myelosuppression occurring that cannot be controlled with other drugs as judged by the investigators
Study: NCT06654843

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Arm
Description: In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced intervention arm
Description: In addition to fitness classes, they will receive childcare in an adjacent space to the fitness class.~In addition to childcare, Arm C will also receive peer support activities. Peer support activities will consist of group volunteer activities at food pantries, free deliveries of food pantry groceries, and group play dates at local playgrounds. A Community Champion will also facilitate group text messages.
Study: NCT06589115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Cuff
Description: The standardized exercises will be performed while wearing a blood flow restriction cuff.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Standard physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Standard physical therapy
Study: NCT06592937

Intervention type: OTHER
Intervention: Invasive ventilation
Description: Invasive ventilation and respiratory support
Study: NCT05287906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Each subject will receive one control and three treatments in the crossover design. The control contains water only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Each subject will receive one control and three treatments in the crossover design. The control contains water only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water
Description: Each subject will receive one control and three treatments in the crossover design. The control contains water only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Each subject will receive one control and three treatments in the crossover design. The glucose contains water and glucose.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steviol Glycosides
Description: Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steviol Glycosides
Description: Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steviol Glycosides
Description: Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside beverage contains water and steviol glycosides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steviol Glycosides plus glucose
Description: Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steviol Glycosides plus glucose
Description: Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steviol Glycosides plus glucose
Description: Each subject will receive one control and three treatments in the crossover design. The Steviol Glycoside plus glucose beverage contains water, glucose, and steviol glycosides.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebaudioside A
Description: A leaf-based, extracted stevia product to compare to the Eversweet in the normal weight group only. The Rebaudioside A contains water and rebaudioside A.